VALEANT PHARMACEUTICALS INTL's ticker is VRX and the CUSIP is 91911K102. A total of 333 filers reported holding VALEANT PHARMACEUTICALS INTL in Q4 2016. The put-call ratio across all filers is 1.34 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2018 | $118,000 | +49.4% | 3,854 | 0.0% | 0.00% | +50.0% |
| Q1 2018 | $79,000 | -21.8% | 3,854 | 0.0% | 0.00% | -33.3% |
| Q4 2017 | $101,000 | +46.4% | 3,854 | 0.0% | 0.00% | +50.0% |
| Q3 2017 | $69,000 | -36.7% | 3,854 | -31.1% | 0.00% | -33.3% |
| Q4 2016 | $109,000 | -28.3% | 5,592 | +18.7% | 0.00% | -57.1% |
| Q3 2016 | $152,000 | -49.0% | 4,713 | +276.1% | 0.01% | -46.2% |
| Q3 2015 | $298,000 | +1652.9% | 1,253 | +1153.0% | 0.01% | +1200.0% |
| Q4 2014 | $17,000 | +13.3% | 100 | 0.0% | 0.00% | 0.0% |
| Q3 2014 | $15,000 | +15.4% | 100 | 0.0% | 0.00% | 0.0% |
| Q2 2014 | $13,000 | -98.0% | 100 | -97.8% | 0.00% | -95.5% |
| Q1 2014 | $654,000 | +16.6% | 4,500 | 0.0% | 0.02% | +29.4% |
| Q4 2013 | $561,000 | +37.5% | 4,500 | +18.4% | 0.02% | +30.8% |
| Q3 2013 | $408,000 | +40.7% | 3,800 | +18.8% | 0.01% | +44.4% |
| Q2 2013 | $290,000 | – | 3,200 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Brave Warrior Advisors | 6,050,442 | $763,082,000 | 30.78% |
| LeVasseur Capital Partners LLC | 190,404 | $24,014,000 | 29.50% |
| FARLEY CAPITAL L.P. | 333,081 | $42,008,000 | 27.09% |
| Ruane, Cunniff & Goldfarb | 34,298,384 | $4,325,712,000 | 23.07% |
| ValueAct Holdings | 18,923,877 | $2,386,679,000 | 17.64% |
| Tesuji Partners | 1,368,040 | $172,537,000 | 17.22% |
| Brahman Capital Corp. | 3,902,877 | $492,231,000 | 13.63% |
| Arrow Capital Management, LLC | 197,500 | $24,909,000 | 13.60% |
| Hound Partners | 2,851,175 | $359,590,000 | 13.45% |
| Ratan Capital Management LP | 731,960 | $92,315,000 | 13.09% |